Your shopping cart is currently empty

5-HT2A inverse agonist-1 is an inverse agonist of the 5-HT2A receptor with an IC50 value of 5.5 nM and negligible inhibition of hERG. This compound is applicable for research into neurological disorders, including Parkinson's disease.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | 5-HT2A inverse agonist-1 is an inverse agonist of the 5-HT2A receptor with an IC50 value of 5.5 nM and negligible inhibition of hERG. This compound is applicable for research into neurological disorders, including Parkinson's disease. |
| Targets&IC50 | 5-HT2A receptor:5.5 nM |
| In vivo | 5-HT2A inverse agonist-1 (Compound P25a) administered orally at a dose of 0.47-4.27 μmol/kg alleviates head twitch symptoms in the rat model induced by DOI. Additionally, 5-HT2A inverse agonist-1 at a dose of 0.51-5.1 μmol/kg reduces locomotor hyperactivity in a rat model induced by MK801. |
| Molecular Weight | 472.46 |
| Formula | C22H25F5N4O2 |
| Cas No. | 3028943-38-3 |
| Smiles | N(CC1=CC=C(F)C=C1)(C(NCC=2C=CC(OCC(F)(F)F)=NC2)=O)[C@@H]3[C@H](F)CN(C)CC3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.